Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419926
Status:
COMPLETED
Last Update Posted:
2011-03-01
First Post:
2007-01-08
Brief Title:
Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Multicenter Parallel-group Open-label Study to Evaluate the Therapeutic Benefit of an Initially Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Dosing Regimen in Combination With Cyclosporine and Corticosteroids in de Novo Renal Transplant Patients
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if an initial intensified enteric-coated mycophenolate sodium Myfortic dosing regimen administered during the first six weeks post renal transplantation provides improved efficacy with a similar safety profile compared to a standard regimen of Myfortic
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None